Research Focus

Research and Technology Management; Senior Analyst, IRB/PB

Recent additions – View all

1. Randomized, double-blind, placebo-controlled phase 3 study of ibrutinib plus rituximab in patients with previously untreated marginal zone lymphoma (MZL)

   Meeting Abstract

   Noy, A.; Hughes, S.; Biggar, E.; Bogdan, M.
   Journal of Clinical Oncology (2021)

   Fulltext@MSK | Save